Inavolisib Plus Palbociclib and Fulvestrant Improves PFS in PIK3CA-Mutated HR+ Breast Cancer
The addition of inavolisib to palbociclib and fulvestrant improved progression-free survival vs palbociclib and fulvestrant alone in select patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative, locally advanced or metastatic breast cancer.
Levi Garraway Global Product Development At Genentech Global Product Development Inavolisib Inavolisib Plus Palbociclib And Fulvestrant Breast Cancer
Source: onclive.com